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Abstract
Background—Fibrillary glomerulonephritis is characterized by randomly arranged fibrils, 
approximately 20 nm in diameter by electron microscopy. Patients present with proteinuria, 
hematuria and kidney insufficiency, and about half of the reported patients progress to end-stage 
kidney disease within 4 years. The dependence of patient characteristics and outcomes on race has 
not been explored. In this study, we describe a cohort of patients with fibrillary glomerulonephritis 
and compare their clinical characteristics and outcomes with those of patients previously 
described.
Methods—The University of North Carolina (UNC) Nephropathology Database was used to 
retrospectively identify patients diagnosed with fibrillary glomerulonephritis between 1985 and 
2015. Of these patients, those treated at UNC were selected. Their demographic and clinical 
characteristics – including signs and symptoms, comorbidities, laboratory values, treatments and 
outcomes – were compared with those of patients described earlier.
Results—Among the 287 patients identified, 42 were treated at the UNC Kidney Center. When 
compared to earlier cohorts, a higher frequency of black race, hepatitis C virus (HCV) infection 
and use of hemodialysis were noted in both black and HCV-positive patients. Autoimmune 
diseases, infections and malignancies were frequently observed, present in over half of all cases.
Conclusion—According to this study, fibrillary glomerulonephritis represents a secondary 
glomerular disease process (associated with autoimmune disease, infection or malignancy) in 
many cases and hence screening is essential. As the screening for comorbidities increased over 
time, more underlying causes were identified. We noted a high frequency of HCV among black 
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patients, suggesting a possible causative association. Treatment of underlying disease is essential 
for patients for the best outcome.
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Introduction
Fibrillary glomerulonephritis is a rare glomerular disease found in less than 1% of native 
kidney biopsies [1, 2]. Initially described in 1977, and later refined, fibrillary 
glomerulonephritis is characterized by the presence of randomly arranged fibrils measuring 
approximately 20 nm in diameter by electron microscopy [3–5]. These fibrils are Congo red 
negative and infrequently identified in the vascular walls or interstitium, distinguishing them 
from amyloid deposits. Light microscopy reveals a spectrum of injury patterns, including 
diffuse mesangial or endocapillary proliferation, with crescents identified in approximately 
25% of cases [6]. Immunofluorescence microscopy typically demonstrates IgG dominance 
(predominantly IgG4) with positive C3 staining [7].
Treatment is challenging and approximately half of all patients progress to end-stage kidney 
disease (ESKD) within 4 years of diagnosis [1, 2, 4, 6, 8]. Although fibrillary 
glomerulonephritis has been associated with autoimmune disorders, infections and 
malignancy [9–15], it is traditionally considered a primary, or “idiopathic,” glomerular 
disease – in contrast to immunotactoid glomerulopathy, which is characterized by the 
presence of larger microtubules arranged in parallel and is strongly associated with 
lymphoproliferative disorders [1, 16–19]. Relationships between clinical characteristics, 
region of residence and race have rarely been explored in fibrillary glomerulonephritis.
In this report, we describe the clinical characteristics (including clinical presentation, 
treatments, outcomes and associations with non-renal diseases) of a cohort of racially 
diverse patients with fibrillary glomerulonephritis residing in the southeastern United States, 
and compare our findings with those previously reported.
Subjects and Methods
Settings and Participants
Patients diagnosed with fibrillary glomerulonephritis by native kidney biopsy between 1985 
and 2015 were identified from the University of North Carolina (UNC) Nephropathology 
Database and the Glomerular Disease Collaborative Network (GDCN), a partnership 
involving the UNC Kidney Center, the UNC Division of Nephropathology and community 
practices in the southeastern United States. This study (UNC IRB #15-1252) was approved 
by the UNC Institutional Review Board (IRB).
Design Overview, Definitions and Data Analysis
The diagnosis of fibrillary glomerulonephritis was based on the presence of randomly 
arranged non-branching fibrils 10–30 nm in diameter, deposited in the mesangium and 
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capillary walls, by electron microscopy. The diagnosis was supported by positive 
immunoglobulin G staining and/or absence of Congo red staining by immunofluorescence 
microscopy. Biopsies must not have histopathological features, indicative of 
cryoglobulinemic glomerulonephritis or immunotactoid glomerulopathy. Patients were 
diagnosed with monoclonal gammopathy of undetermined significance (MGUS) if they had 
a monoclonal protein present on serum protein electrophoresis or immunofixation, but did 
not meet diagnostic criteria for multiple myeloma. They were classified as having 
monoclonal gammopathy of renal significance (MGRS) if they did not meet the criteria for 
multiple myeloma, but a hematologist considered their monoclonal gammopathy to be a 
contributing factor to kidney dysfunction.
We retrospectively extracted demographic and clinical data from patient medical records, 
including presenting signs and symptoms, comorbidities, laboratory values, treatment and 
outcomes at the time of kidney biopsy. More recent kidney function status was classified as 
non-progressive (serum creatinine remained stable, improved or increased <25% of the 
original value after treatment), progressive (serum creatinine increased >25% of the original 
value during biopsy) or ESKD [3, 20, 21]. Primary outcomes were reported based on the last 
available clinic visit or report (as death, dialysis, transplant or doubling of serum creatinine). 
Data were compared with published cohorts of patients with fibrillary glomerulonephritis 
found on PubMed using the MeSH terms “glomerulonephritis” and “fibrillary” combined 
with Boolean operator “AND” to maximize sensitivity.
Statistical Analysis
Statistical analysis was performed using Prism 5.0 (GraphPad). Continuous variables were 
reported as means with SDs and compared with the Mann–Whitney test. Categorical 
variables, reported as frequencies and percentages, were compared with the Fisher’s exact 
test or chi-square as appropriate. Kaplan–Meier survival analysis was used to compare time 
to kidney impairment. A twosided significance level of p < 0.05 was assumed.
Results
Demographic and Clinical Characteristics
Between 1985 and 2015, 287 cases with a histopathological diagnosis of fibrillary 
glomerulonephritis were evaluated by UNC nephropathologists, and the UNC Kidney Center 
prescribed treatment for 42 patients (Table 1). Demographic and clinical characteristics of 
patients evaluated at the UNC Kidney Center were comparable to those of the entire 
biopsied cohort.
Demographic, laboratory and comorbidity characteristics at the time of biopsy are 
summarized in Table 2 for patients who were prescribed treatment at the UNC Kidney 
Center. Most patients had hematuria (95%), proteinuria (97%) and kidney impairment (mean 
creatinine 3.2 mg/dL) at presentation. Serum creatinine was found to be higher in black 
patients compared to white patients (4.7 vs. 2.7 mg/dL, p = 0.01), and black patients were 
more likely to have transitioned to dialysis (82 vs. 30%, p = 0.004). Hepatitis C virus (HCV) 
infection was more common in black patients compared to white patients (7 vs. 0 patients, p 
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< 0.001). There were no statistical differences based on sex in our population (online suppl. 
Table 1; for all online suppl. material, see www.karger.com/doi/10.1159/000455390).
Further evaluation of the HCV-positive patient population determined that these patients 
were younger than the HCV-negative patients (50 vs. 58 years, p = 0.02) and were more 
likely to be black (100 vs. 16%, p < 0.001; Table 2). Although the status of hepatitis was not 
tested for all patients, HCV infection was more common at the UNC Kidney Center 
compared to previously published data (26%; Table 3). Serum cryoglobulins were measured 
and undetectable in 4 of the 7 patients who were HCV positive. None of the 7 patients had 
diagnostic features of cryoglobulinemic glomerulonephritis on biopsy. Serum albumin was 
similar in HCV-positive and HCV-negative patients (2.9 vs. 3.2 g/dL, p = 0.66) and C3 was 
not substantially lowered in HCV-positive patients, suggesting that the liver function was not 
severely altered. This was further supported by normal liver function tests and/or absence of 
cirrhosis by imaging in these patients. HCV-positive patients were more likely to be 
transitioned to dialysis than patients with negative HCV serologies (89 vs. 26%, p = 0.02).
A review of the literature revealed 6 earlier reports of cohorts containing 9 or more patients 
with fibrillary glomerulonephritis, along with one study that summarized published reports 
between 1977 and 1994 (online suppl. Table 2). A qualitative comparison of patients in these 
published cohorts with those in our cohort showed similar laboratory values at the time of 
biopsy including serum creatinine (online suppl. Table 2). The cohort in the study had a 
higher percentage of black patients (28 vs. 0–10%) compared to other cohorts, reflecting 
local demographics. Comorbidities in our cohort were similar to those previously reported, 
with the exception of HCV, which was more common in our cohort; however, many studies 
did not report comorbidities (Table 3). Fifty-eight percent of our patients had a concomitant 
autoimmune disorder, infection or malignancy.
Autoimmune disorders have been identified in other cohorts, affecting 3–30% of patients 
with fibrillary glomerulonephritis. Ten percent of patients in our cohort had an autoimmune 
disorder. Six patients (12%) had a solid tumor malignancy (including basal cell and 
squamous cell carcinoma of the skin, renal carcinoma, breast carcinoma and non-squamous 
cell lung carcinoma). There were 4 patients with MGUS and 2 patients with MGRS treated 
with a multiple myeloma chemotherapy regimen. Of note, none of these patients had 
monoclonal immunoglobulin deposition on immunofluorescence microscopy.
Histopathology
The average number of glomeruli examined on light microscopy was 18 (range 4–67), with 
an average of 29% glomeruli globally sclerosed and 5% crescentic. The percentage of 
globally sclerotic glomeruli was increased in black patients (39% vs. non-black 25%, p = 
0.18), HCV-positive patients (34% vs. HCV negative 25%, p = 0.71), and patients who 
progressed to ESKD (41 vs. 22%, p = 0.02). Interstitial fibrosis and tubular atrophy (IFTA) 
were observed in 92% of kidney biopsies (characterized as 26% mild, 40% moderate, 26% 
severe). IFTA was more severe in patients with outcomes of ESKD (p = 0.03 vs. those 
without). Differences in IFTA between black and non-black patients (p = 0.06) and HCV-
negative and HCV-positive patients (p = 0.28) were not significant. Similarly, 
arteriosclerosis increased in patients with outcomes of ESKD (p = 0.01), while there were no 
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significant differences based on race (p = 0.16) and HCV status (p = 0.22). 
Immunofluorescence staining pattern was positive for IgG (kappa and lambda) in 95% of 
biopsies, followed closely by C3 (positive in 91% of biopsies), C1q (65%), IgM (56%) and 
IgA (39%).
Treatments
In our cohort, 3 patients (7%) received no treatment due to the severity of kidney disease and 
significant degree of tubulointerstitial scarring at the time of presentation deeming the 
treatment futile. Hemodialysis was initiated in 3 patients (7%) at the time of presentation. 
Renin-angiotensin-aldosterone system (RAAS) blockade alone was instituted in 24% of 
patients (n = 10), and RAAS blockade in conjunction with an immunomodulating agent was 
prescribed in 36% (n = 15) of patients.
Five prior studies reported treatment data on the use of immunosuppressive therapy (Table 
3). We found that the inclusion of corticosteroids in the treatment plan was less common in 
our cohort compared to others. There has been a notable increase in rituximab use over time, 
with 17% of patients receiving rituximab in 2011, 54% in 2013 and 75% in our group [22, 
23].
In our cohort, 15 patients were advised to initiate rituximab (online suppl. Table 3). Nine 
patients were classified by outcome as a result of treatment. Outcomes were similar to 
previously reported rituximab data as 11% were non-progressive, 56% were progressive and 
33% reached ESKD [21]. Patients in our cohort whose outcome was ESKD had a longer 
time from biopsy to rituximab dose (30 vs. 4.5 months, p = 0.05), higher average creatinine 
at the time of rituximab treatment (3.22 vs. 2.27 mg/dL, p = 0.38), and the initial 
biopsy revealed a higher percentage of sclerosis (49 vs. 22%, p = 0.02).
Outcomes
Despite having a higher average serum creatinine at the time of diagnosis, patients in our 
cohort had similar patient and kidney survival when compared to prior reports (Table 3). Of 
patients that are still being managed by our group, 6 (19%) are on dialysis with a 13-month 
median time to dialysis initiation (15/42 patients) for our entire cohort. Twenty-three percent 
(n = 7) of patients were lost to follow-up or have not been seen in the UNC Hospitals system 
within the last 2 years. Two patients have had a transplant without recurrence and 52% of 
patients in the cohort are still actively followed and are free from ESKD or doubling of 
creatinine. Of these 16 patients, the median time from diagnosis to last visit was 16 months 
(interquartile range 9–82) and the mean creatinine was 2.5 ± 1 mg/dL, glomerular filtration 
rate (GFR) was 29 ± 15 and UPC was 4.6 ± 7.
The rate of primary renal outcome (a composite of doubling of serum creatinine, initiation of 
dialysis, transplant or death) was similar in males and females (p = 0.38; Fig. 1a), but was 
significantly higher in black compared to white patients (p = 0.02; Fig. 1b). Kidney survival 
was not significantly different between HCV-positive and HCV-negative patients, but the 
small sample size limited this evaluation (p = 0.06; Fig. 1c). There was no difference in 
kidney survival in HCV-negative black versus white patients (p = 0.22).
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Discussion
In this study, we report the clinical features and outcomes of patients with fibrillary 
glomerulonephritis diagnosed in the southeastern United States and compare patient 
characteristics in this cohort with those of patients described in prior reports. Prior studies 
have predominantly focused on patients of European descent [1, 8, 21–24], and this is the 
first study to focus on patients in the southeastern United States, where the black race is 
prevalent. Compared to prior cohorts, our patients were more likely to be black and have 
coexisting HCV infection. Black patients were more likely to be transitioned to dialysis and 
have decreased kidney survival time compared to white patients. Patients with HCV were 
more likely to progress to ESKD and transition to dialysis compared to patients without 
HCV. However, black patients without HCV had similar outcomes compared to white 
patients without HCV. Although black patients represent 12% of the United States 
population, they comprise 22% of HCV-positive individuals [25]. The percentage of black 
patients with fibrillary glomerulonephritis treated in our clinic closely reflects the racial 
composition of the southeastern United States [26]. Unlike other glomerular diseases such as 
lupus nephritis, membranous nephropathy and ANCA glomerulonephritis that have a 
predilection for specific racial groups, our cohort demonstrates that fibrillary 
glomerulonephritis is evenly distributed among patients of different races, a finding not 
reported earlier.
Our study also supports an association between fibrillary glomerulonephritis and infections, 
malignancy and autoimmune disorders, as over half of our patients had one of these 
comorbidities, higher than previously reported. Furthermore, a recent study of 66 patients 
with fibrillary glomerulonephritis from the Mayo Clinic (95% Caucasians) found that one 
third of patients had malignancy, autoimmune disease or monoclonal gammopathy [22]. It 
was proposed that while fibrillary glomerulonephritis has been traditionally considered a 
primary glomerular disease, all patients should be screened for secondary causes as part of 
their initial evaluation. This proposed recommendation has both diagnostic and therapeutic 
implications, as treatment of the associated comorbidity may lead to the resolution of the 
glomerular disease process.
An association between HCV infection and fibrillary glomerulonephritis has been previously 
described [27, 28]. However, our cohort is unique in that one third of patients tested were 
positive for HCV, which is much higher than previously reported. While the exact etiology 
of fibrillary glomerulonephritis is largely unknown, pathogenesis likely relates to the 
deposition of immune complexes containing IgG and complement: HCV is a plausible 
candidate to elicit such an immune response [27]. All of our patients with HCV were 
diagnosed before the availability of direct-acting antiviral therapy, and none were treated 
with older agents for a sustained period of time. Neither were any of these patients treated 
with rituximab, which was used in the treatment of HCV-related cryoglobulinemic 
glomerulonephritis. Future studies are warranted to investigate the presence of HCV viral 
antigens within the immune deposits in fibrillary glomerulonephritis, and to explore the use 
of antiviral therapies in eradicating glomerular disease activity.
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Since fibrillary glomerulonephritis involves glomerular deposition of immunoglobulin, a 
rationale for the use of the CD20-positive B-cell depleting agent rituximab exists, especially 
in patients with comorbid humoral autoimmune disease. Published outcomes of rituximab 
treatment are varied. In a study of 3 adults (presenting with serum creatinine from 0.6 to 1.3 
mg/dL with a follow-up of 9–46 months), kidney disease was stabilized [29]. The outcomes 
of a study of 7 patients (average estimated GFR [eGFR] of 66 mL/min/1.73 m2, mean 
follow-up of 44 months) were 2 patients with no response, one with complete response and 4 
with partial response to rituximab [23]. Twelve patients treated with rituximab (average 
serum creatinine of 2.1 mg/dL and eGFR of 39 mL/min/1.73 m2) resulted in 33% of patients 
with stabilized kidney function, however, these patients had lower serum creatinine levels 
prior to treatment (average 1.25 mg/dL). Patients whose kidney function deteriorated (25%) 
had a mean serum creatinine of 1.93 mg/dL, and patients that progressed to ESKD (42%) 
had a mean serum creatinine of 2.5 mg/dL at presentation. In our cohort, delayed initiation 
of rituximab treatment, increased creatinine at the time of treatment and higher rates of 
sclerosis at the time of biopsy were more likely to result in a patient with an outcome of 
ESKD (online suppl. Table 3). Given that many of our patients received other treatments in 
addition to rituximab, we speculate that treatment with rituximab slows the progression to 
ESKD and may be beneficial if used swiftly after disease diagnosis.
Our retrospective study has several limitations. Complete demographic and clinical 
characteristics of all 287 patients whose native kidney biopsies were interpreted at UNC are 
lacking; however, age, race, sex, entry serum creatinine, eGFR, serum albumin and 
proteinuria were not statistically different between this larger group and the 42 patients who 
were treated at UNC and further analyzed. Our findings also reflect the treatment practices 
of one institution, and cannot necessarily be generalized to other patient cohorts. Few 
patients received rituximab, and those who did were mainly treated in the more modern era, 
limiting their follow-up duration. None of the HCV patients were treated with newer 
antiviral agents; thus, we cannot determine whether effective eradication of the virus might 
lead to glomerular disease resolution. Finally, our sample size was small – due to the rarity 
of this disease – and thus our statistical power to detect between-group differences by race, 
HCV status and sex, was limited.
Our findings provide new insights into the demographic and clinical characteristics of 
patients with fibrillary glomerulonephritis, and explore the influence of race and 
comorbidity on disease onset and progression. A distinct subgroup of patients of black race 
with co-existing HCV infection, who appear to have a particularly poor prognosis, was 
identified for the first time. This vulnerable patient group may benefit from a combination of 
antiviral and rituximab therapies to eradicate their immune-complex mediated glomerular 
disease, although this hypothesis requires further study. Importantly, our findings also 
suggest that screening for infections, malignancy and autoimmune diseases may be 
warranted in all patients presenting with this rare disease entity, as the potential for fibrillary 
glomerulonephritis to be a secondary disease process may have been under-appreciated in 
prior reports. In addition, proteomic profile studies of the deposits in fibrillary 
glomerulonephritis suggest that the presence of apolipoprotein E and immunoglobulin light 
or heavy chain C region may be key to the organization and tissue deposition, making these 
potential targets of future therapies [30]. Further investigation into disease pathogenesis and 
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appropriate treatment through multi-center collaborations and well-conducted randomized 
controlled clinical trials is warranted.
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Fig. 1. 
a–c Kaplan–Meier estimates of significant loss of kidney function. Kidney function was 
defined as impaired if there was a doubling of serum creatinine since biopsy, initiation of 
dialysis, transplant or death. Estimated glomerular filtration rate at diagnosis was similar 
between groups.
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Table 1
The UNC Kidney Center cohort of patients with fibrillary glomerulonephritis is a representative sample of the 
entire cohort of patients within the UNC Nephropathology database
UNC nephropathology 2015 (n = 245) UNC Kidney Center 2015 (n = 42)
Age, years  57±12  54±10
Race, %
 White  68  71
 Black  16  26
 Other/unknown  16   2
Female, %  62  60
Serum creatinine, mg/dL 3.3±3 (155) 3.0±3 (36)
eGFR, mL/min/1.73 m2  34±27 (155)  35±20 (35)
Albumin, g/dL 3.1±1 (77) 3.1±1 (23)
Proteinuria, g/24 h 4.8±4 (113) 5.7±5 (33)
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